الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 116 |  |  |
| | | from | 116 | | |
Abstract
Human hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Polymorphisms of the TP53 gene are known to play an important role in HCC. We aimed to investigate the impact of the Arg72Pro polymorphism of TP53 in the development of HCC. We also investigated the relation between the TP53 Arg72Pro polymorphism and the plasma TP53 levels in HCC patients.
This study included 69 HCC patients, 101 liver cirrhosis (LC) patients and 46 healthy, unrelated, age-matched volunteers as controls, from the same locality of Egypt. The HCC and LC patients were suffering from HCV infection.
The results showed that the Proline allele significantly increases the risk of HCC development (OR 2.461, 95 % CI 1.391-4.3558, p = 0.002, Z* = 3.094), compared with the development of LC. The variant genotypes were also associated with the risk of HCC (Pro/Pro: OR 3.7956, 95 % CI 1.9228 -7.4923, p = 0.0001; Arg/Pro: OR 2.099, 95 % CI 1.0911 – 4.0383, p = 0.0263; Arg/Arg: OR 1.9594, 95 % CI 1.0023 – 3.8306, p = 0.0492). There was a significant increase in the plasma TP53 level in the HCC group when compared with the LC group or with the control group (P = 0.000).
This case control-analysis confirmed that Pro allele of codon 72 of TP53 gene is associated with increased risk of HCC in HCV-infected patients. Also there were significant decrease in plasma TP53 levels in all studied groups in HCC patients. To validate this association; further studies with larger participants worldwide and extended markers close to Arg72Pro marker are needed to examine the association between this polymorphism and HCC.